Millie
your market intelligence analyst
Search Results
156 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
National Law Review 09/20/2019 17:05
The stream of commerce theory was not discussed in BMS, as the purposeful availment requirement was not contested.
More from National Law Review:
Zacks.com 09/20/2019 10:49
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil.
More from Zacks.com:
Business Wire 09/20/2019 06:59
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights.
More from Business Wire:
Bristol-Myers Squibb 09/11/2019 16:16
Dateline City:. NEW YORK. NEW YORK--()--The Board of Directors of (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.41) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 1, 2019, to stockholders of record at the close of business on October 4, 2019. The directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable December 2, 2019 to stockholders of record at the close of business on November 5, 2019. Language:. English. Contact:. Media: Carrie Fernandez, 609-252-5222, Investors: Tim Power, 609-252-7509,. Ticker Slug:. Ticker:. BMY. Exchange:. NYSE.
The Scientist 09/11/2019 10:27
Leading industry experts from some of the most influential pharmaceutical, biotech companies, and institutions in the world such as Bristol Myers Squibb, Boehringer Ingelheim, and the Huntsman Cancer Institute will provide insight on using high throughput surface plasmon resonance (SPR) technology to explore the full kinetic and epitope diversity of antibody libraries.
Pharmafile 09/11/2019 05:06
BMS unveils strong five-year efficacy data for Opdivo in lung cancer.
More from Pharmafile:
NASDAQ 09/10/2019 03:08
Bristol-Myers Squibb ( BMY ) generates its revenue from sales of pharmaceuticals drugs for various therapeutic areas, including cardiovascular, virology, oncology, and immunology.
More from NASDAQ:
FiercePharmaManufacturing 09/09/2019 19:12
At the five-year mark, use of Opdivo in previously treated NSCLC patients delivered survival rates more than five times as high as docetaxel chemotherapy did, BMS said at the World Conference on Lung Cancer in Barcelona.
More from FiercePharmaManufacturing:
3BL Media 09/09/2019 11:20
DESCRIPTION:. As victims in the Bahamas continue to feel the devastation of #HurricaneDorian, the Bristol-Myers Squibb Foundation is committed to supporting disaster relief partners, Americares, Direct Relief International and American Red Cross, with a donation to provide needed supplies and medical care to the impacted communities to help alleviate the suffering.
pharmaphorum 09/06/2019 04:33
BMS said that the trial in newly-diagnosed glioblastoma multiforme failed to meet one of its primary endpoints, progression-free survival.
More from pharmaphorum:
ENDPOINTS 09/05/2019 08:51
Bristol-Myers has had a string of setbacks in the clinic with Opdivo, though the pharma giant still enjoys blockbuster revenue even as Merck’s Keytruda continues its clinical blitz that put them on top of the ...
More from ENDPOINTS:
MarketWatch 09/05/2019 07:24
Bristol-Myers said the data monitoring committee recommended that the trial continue as planned, to allow the other primary endpoint of overall survival to mature.
More from MarketWatch:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications